Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-564: Pembrolizumab as Adjuvant Therapy in Renal Cell Carcinoma Post Nephrectomy
2016-004351-75Phase 3Active
- Sponsor
- Merck & Co.
- Start
- Mar 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in renal cell carcinoma (RCC) comparing Pembrolizumab adjuvant monotherapy with Placebo (2 arms). Primary endpoint: Disease-free survival. Started Mar 2017; status: active.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2016-004351-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004351-75.